In 2012, the European Union (EU) introduced regulatory controls for good pharmacovigilance practices (GVPs) to its member states. Since then, pharma businesses operating in the EU, and those providing pharmacovigilance (PV) services to them, have experienced significant change. David Hukin of Quanticate maps out the regulatory landscape and the impact these changes are having on the industry.